drugset / Trial / NCT02579434

Evaluation and Validation of Endogenous Markers for the Assessment of CYP3A Activity in Korean Healthy Subjects Using Metabolomics

NCT02579434 ↗

Phase 1 Completed 102 enrolled Seoul National University Hospital
Non-randomizedParallel-groupOpen-label

Summary

The study objective is to evaluate and validate of endogenous markers for the assessment of CYP3A activity in Korean healthy subjects using metabolomics. In part 1, total 75 healthy subjects (males and females) will be enrolled. In part 2, total 25 healthy female subject aged 20-45 years will be enrolled. In both part A and B, subjects will be administered midazolam I.V. 1 mg.

Timeline

Start
2014-12
Primary completion
2015-05
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Midazolam Small molecule 1 mg/ml Intravenous

Indications

No indication recorded.